EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer

Preeti Narayan iD, Asma Dilawari iD, Christy Osgood, Zhou Feng iD, Erik Bloomquist iD, William F Pierce iD, Samina Jafri iD, Shyam Kalavar, Marina Kondratovich, Prakash Jha iD, Soma Ghosh, Shenghui Tang iD und 3 weitere

Journal of Clinical Oncology · 10.04.2023 · 41 (11) · 2108-2116

DOI: 10.1200/jco.22.02447 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2023. Verfasst von Preeti Narayan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The US Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (DS-8201a, T-DXd) for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry 1 + or immunohistochemistry 2+/in situ hybridization–) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. PATIENTS AND METHODS Approval was based on DESTINY-Breast04, a phase III, randomized, open-label, multicenter trial in patients with unresectable or metastatic HER2-low breast cancer, determined at a central laboratory. A total of 557 patients were randomly assigned (2:1) to receive either T-DXd 5.4 mg/kg intravenously once every 3 weeks (n = 373) or physicians' choice of chemotherapy (n = 184). RESULTS The study met its primary efficacy end point of progression-free survival (PFS) by blinded independent central review assessment in the hormone receptor–positive (HR+) cohort (N = 494) with an estimated hazard ratio (HR) of 0.51(95% CI, 0.40 to 0.64; P < .0001). Key secondary end points were also met, including PFS in the intent-to-treat population with an HR of 0.50 (95% CI, 0.40 to 0.63; P < .0001), overall survival (OS) in the HR+ cohort with an HR of 0.64 (95% CI, 0.48 to 0.86; P = .0028) and OS in the intent-to-treat with an HR of 0.64 (95% CI, 0.49 to 0.84; P = .0010). The safety profile of T-DXd was consistent with previously approved indications, and no new safety signals were observed in this study population. CONCLUSION The approval of T-DXd in HER2-low metastatic breast cancer was based on statistically significant and clinically meaningful PFS and OS improvements observed in the DESTINY-Breast04 trial and represents the first approved therapy specifically for the treatment of HER2-low metastatic breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsUnited StatesAdultHumansFemaleUnited States Food and Drug AdministrationAntibodies, Monoclonal, HumanizedNeoplasm Recurrence, LocalTrastuzumabErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsCamptothecinImmunoconjugates

Substanzen

Antibodies, Monoclonal, HumanizedTrastuzumabErb-b2 Receptor Tyrosine Kinasestrastuzumab deruxtecanCamptothecinImmunoconjugatesERBB2 protein, human

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD.
  • Center for Devices and Radiological Health (CDRH), US Food and Drug Administration, Silver Spring, MD.
  • Oncology Center of Excellence (OCE), US Food and Drug Administration, Silver Spring, MD.

ORCID-Profile: Preeti Narayan, Asma Dilawari, Zhou Feng, Erik Bloomquist, William F Pierce, Samina Jafri, Prakash Jha, Shenghui Tang, Richard Pazdur, Laleh Amiri-Kordestani

Zitieren

APA

Narayan, P., Dilawari, A., Osgood, C., Feng, Z., Bloomquist, E., Pierce, W. F., Jafri, S., Kalavar, S., Kondratovich, M., Jha, P., Ghosh, S., Tang, S., Pazdur, R., Beaver, J. A., & Amiri-Kordestani, L. (2023). US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. Journal of Clinical Oncology, 41(11), 2108-2116. https://doi.org/10.1200/jco.22.02447

Vancouver

Narayan P, Dilawari A, Osgood C, Feng Z, Bloomquist E, Pierce WF, et al. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. Journal of Clinical Oncology. 2023;41(11):2108-2116. doi:10.1200/jco.22.02447

BibTeX
@article{Narayan2023,
  author = {Narayan, Preeti and Dilawari, Asma and Osgood, Christy and Feng, Zhou and Bloomquist, Erik and Pierce, William F and Jafri, Samina and Kalavar, Shyam and Kondratovich, Marina and Jha, Prakash and Ghosh, Soma and Tang, Shenghui and Pazdur, Richard and Beaver, Julia A and Amiri-Kordestani, Laleh},
  title = {US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {11},
  pages = {2108--2116},
  doi = {10.1200/jco.22.02447}
}
Kostenlos starten →